Macroaxis Stories

Our latest take on Neogen (NASDAQ:NEOG) analyst consensus

September 21, 2021  By
Neogen Cp is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 28th of September 2021. As some millenniums are still trying to avoid healthcare space, I will try to digest Neogen Cp a little further in order to understand its potential as a viable investment. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over a year ago
View all stories for Neogen | View All Stories

Reviewed by Raphi Shpitalnik

Neogen Cp is UNDERVALUED at 48.75 per share with modest projections ahead.
Neogen Cp trade recommendations module can be used to check and cross-verify current advice provided by analysts analyzing the firm's potential to grow using all of fundamental, technical, data market data available at the time.
What is the right price you would pay to acquire a share of Neogen? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Neogen this year

Annual and quarterly reports issued by Neogen are formal financial statements that are published yearly and quarterly and sent to Neogen stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Neogen often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How important is Neogen's Liquidity

Neogen financial leverage refers to using borrowed capital as a funding source to finance Neogen ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Neogen financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Neogen's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Neogen's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Neogen's total debt and its cash.

Is Neogen a risky opportunity?

Let's check the volatility. Neogen is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Neogen (NASDAQ:NEOG) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. purchasing a share of a Neogen Cp stock makes you a part-owner of that company.

Neogen Cp Current Consensus

Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Neogen Cp. The Neogen consensus assessment is calculated by taking the average estimates from all of the analysts covering Neogen Cp
Strong Buy
1
Hold
2
Strong Buy133.33
Buy00.0
Hold266.67
Sell00.0
Strong Sell00.0

Are Neogen Cp technical ratios showing a reversion?

The jensen alpha is down to -0.21 as of today. Neogen Cp exhibits very low volatility with skewness of -0.11 and kurtosis of 0.65. However, we advise investors to further study Neogen Cp technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Neogen Cp's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Neogen Cp's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Neogen Cp

Although many of the other players within the diagnostics & research industry are still a little expensive, even after the recent corrections, Neogen Cp may offer a potential longer-term growth to shareholders. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither pick up nor exit any shares of Neogen Cp at this time. The Neogen Cp risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Neogen Cp.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Neogen. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com